Page 1of 52
Title
DD T2 Daily Disposable Registration Trial
Protocol Number:
Development Stage of 
Project:
Sponsor Name and 
Address:
Test Product:
Investigator Agreement:CLE383-C 005 / [STUDY_ID_REMOVED]
Development
Alcon Research, Ltd. and its 
affiliates (“Alcon”)
6201 South Freeway
Fort Worth, Texas 76134-2099
DD T2
I have read the clinical study described her ein, and recognize its 
confidentiality . I agree to conduct this study in accordance with 
the ethi
cal principles contained within the Declaration of 
Helsinki, and the described study in compliance with the 
protocol, Good Clinical Practice (GCP), I SO 14155, and all 
applicable regulatory requirements. Additionally , I will comply 
with all procedures for d ata recording and reporting, will permit 
monitoring, auditin
g, and inspection of my research center, and 
will retain all records until notified by the Study Sponsor.
Principal I nvestigator:
Signature Date
Name and professional 
position:
Address:
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 2of 52
Table of Contents
Table of Contents .......................................................................................................................2
List of T ables ..............................................................................................................................4
List of Figures ............................................................................................................................5
1
GLOSSAR Y OF TERMS ....................................................................................................6
2LIST OF ACRONYMS AND ABBREVIA TIONS ...........................................................10
3PROT OCOL  SUMMAR Y
.................................................................................................12
4PROT OCOL  AMENDMENTS .........................................................................................18
4.1 Amendments ......................................................................................................18
5INTRODUCTION .............................................................................................................18
5.1 Rationale and Background ................................................................................18
5.2 Purpose of the Study ..........................................................................................19
5.3 Risks and Benefits .............................................................................................19
6STUDY  OBJECTI VES ......................................................................................................20
6.1 Primary  Objective ..............................................................................................20
6.2 Secondary  Objective ..........................................................................................20
20
6.4 Safety  Objective(s) ............................................................................................20
7INVESTIGA TIONAL  PLAN ............................................................................................21
7.1 Study  Design .....................................................................................................21
7.2 Rationale for Study  Design ...............................................................................22
7.3 Rationale for Duration of Treatment/Follow -Up...............................................23
7.4
Rationale for Choice of Control Product................................ ...........................23
7.5 Data Monitoring Committee ..............................................................................23
8STUDY  POPULA TION....................................................................................................23
8.1 Inclusion Criteria
...............................................................................................23
8.2 Exclusion Criteria ................................ ................................ ..............................24
8.3 Rescreening of Subjects ................................ ................................ ....................25
9TREA TMENTS ADMINISTERED ................................ ................................ ...................25
9.1 Investigational Product(s) ................................ ................................ ..................25
9.2 Other Medical Device or Medication Specified for Use During the Study ......28
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 3of 52
9.3 Treatment Assignment / Ra ndomization ...........................................................29
9.4 Treatment masking ............................................................................................29
9.5 Accountability  Procedures .................................................................................31
9.6
Changes to concomitant medications, treatments/ procedures..........................32
10STUDY  PROCEDURES AND ASSESSMENTS .............................................................32
10.1 Informed Consent and Screening
......................................................................33
10.2 Description of Study  Procedures and Assessments ...........................................33
10.2.1 Demographics ....................................................................................33
10.2.2 Medical History .................................................................................33
10.2.3
Investigational Product compliance ..................................................34
10.2.4 Adverse Event Collection: Safety  Assessment ..................................34
10.2.5 Slit-Lamp Biomicroscopy : Safet y Assessment .................................34
10.2.6 Device Deficiencies: Safety  Assessment ...........................................34
10.2.7 Additional Study  Assessments: Ef fectiveness and Safety  Assessments
...........................................................................................................34
10.3 Unscheduled V isits............................................................................................35
10.4 Discontinued Subjects .......................................................................................35
10.4.1 Screen Failures ..................................................................................35
10.4.2 Discontinuations ................................................................................35
10.4.3 Schedule of Procedures and Assessments for Subjects Discontinued 
from Investigational Product
.............................................................36
10.5 Clinical Study  Termination ................................................................................36
10.5.1 Follow -up of subjects after study  participation has ended ................
37
11ADVERSE EVENTS AND DEVICE DEFICIENCI ES...................................................37
11.1
General Information ..........................................................................................37
11.2Monitoring for Adverse Events ................................ ................................ .........40
11.3 Procedures for Recording and Reporting ................................ ..........................40
11.4Return product anal ysis.....................................................................................42
11.5Unmasking of the 
Study  Treatment................................ ................................ ...42
11.6Follow -Up of Subjects with Adverse Events ................................ .....................43
11.7Pregnancy  in the Clinical Study ................................ ................................ ........43
12ANAL YSIS PL AN................................ ................................ ................................ ............43
12.1 Subject Evaluability ................................ ................................ ...........................43
12.2 Analy sis Sets ................................ ................................ ................................ .....44
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Page 4of 52
12.3 Demographic and Baseline Characteristics.......................................................44
12.4 Effectiveness Anal yses......................................................................................44
12.4.1 Analy sis of Primary  Effectiveness Endpoint .....................................44
12.4.1.1 Statistical Hy potheses ........................................................45
12.4.1.2 Analy sis Methods ..............................................................45
45
......................45
46
12.5
Handling of Missing Data .................................................................................46
12.6 Safety  Analyses.................................................................................................46
12.7 Interim Anal yses and Reporting ........................................................................46
46
13DATA HANDLING AND ADMINISTRA TIVE REQUI REMENTS ...............................
47
13.1 Subject Confidentiality ......................................................................................47
13.2 Completion of Source Documents and Case Report Forms ..............................
47
13.3 Data Review and Clarifications.........................................................................48
13.4 Sponsor and Monitoring Responsibilities .........................................................48
13.5 Regulatory  Documentation and Records Retention ..........................................49
13.6 Quality  Assurance and Quality  Control .............................................................49
14ETHI CS.............................................................................................................................50
15REFERENCES ..................................................................................................................51
15.1
References applicable for all clinical studies ....................................................51
15.1.1
US references applicable for clinical studies .....................................51
15.2 References for this clinical study ......................................................................52
List of Tables
Table2–1 List of Acron yms and Abbreviations Used in This Protocol ........................... 10
Table3–1 Schedule of Study  Procedures and Assessments ................................ .............16
20
Table6–2 Safety  Objective(s) ................................ ................................ ...........................20
Table9–1 Test Product ................................ ................................ ................................ .....25
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 5of 52
Table9–2 Control Product ................................ ................................ ................................27
Table9–3 Unmasked Individuals Associated with the Study ................................ ...........29
Table10-1 Study  Visits ................................ ................................ ................................ ......32
List of Figur es
Figure 7–1 Flowchart of Study  Visits................................ ................................ .................22
Figure 11–1 Categorization of All Adverse Events ................................ ..............................37
Figure 11-2 Categorization of All Serious Adverse Events .................................................38
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Page 6of 52
1GLOSSAR Y OF TERMS
Names of test product Throughout this document, Test product will be referred to 
as DD T2.
Name of Control Product Alcon DAILIES TOT AL1®(delefilcon A)(DT1)
Adverse Device Ef fect AEs related to the use of a n investigational medical device
(test product )or control product. Note: This definition 
includes AEsresulting fr om insufficient or inadequate 
instructions for use, deployment, implantation, installation, 
or operation; any malfunc tion; and use err or or intentional 
misuse of the test pr oduct or contr ol pr oduct.
Adverse Event (AE) Any untoward medical occurrence, unintended disease or 
injury , or untoward clinical signs (including abnormal 
laboratory  findings) in subjects, users or other persons, 
whether or not related to the investigational medical device 
(test product). Note: For s ubjects, this definition includes 
events r elated to the test pr oduct, the contr ol product, or the 
procedur es involved. For users or other persons, this 
definition is r estricted to events r elated to the test pr oduct.
Requirements for reporting AEs in the st udy can be found in 
Section 11.
Anticipate d Serious 
Adverse Device Ef fectSerious adverse device effect which b y its nature, incidence, 
severit y,or outcome has been identified in the risk 
management file.
Device Deficiency Inadequacy  of a medical device with respect to its identity , 
quality , durability , reliability , safety , or performance. Note: 
This definition includes malfunctions, use err ors, and 
inadequate labeling.
Requirements for reporting Device Deficiencies in the study  
can be found in Section 1 1.
Enrolled Subject Any subject who signs an informed consent form for 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Pa ge 7of 5 2 
partici pati o n i n t he st u d y .
I nter ve nti o nal Cli nical T rial A researc h trial t hat pr os pecti vel y assi g ns, w het her 
ra n d o ml y  or n ot, h u ma n partici pa nts or gr o u ps of h u ma ns t o 
o ne or m ore healt h -relate d i nter ve nti o ns t o e val uate t he 
eff ects o n healt h o utc o mes, a n d/ or a researc h trial i n w hic h 
dia g n ostic or m o nit ori n g pr oce d ures be y o n d sta n dar d of care 
are c o n d ucte d a n d ge nerate o utc o mes f or use i n a nal y sis of 
data. 
I n vesti gati o nal Pr o d uct Is defi ne d as a pre ve ntati ve ( vacci ne), a t hera pe utic ( dr u g or 
bi ol o gic), de vice, dia g n ostic, or palliati ve use d as a test or 
c o ntr ol pr o d uct i n a cli nical trial, i ncl u di n g a pr o d uct wit h a 
mar keti n g a ut h orizati o n w he n use d or asse m ble d 
(f or m ulate d or pac ka ge d) i n a wa y  differe nt fr o m t he 
a ut h orize d f or m, or w he n use d f or a n u na ut h orize d 
i n dicati o n, or w he n use d t o gai n f urt her i nf or mati o n a b o ut 
t he a ut h orize d f or m .
Malf u ncti o n Fail ure of a me dical de vice t o meet its perf or ma nce 
s pecificati o ns or ot her wis e perf or m as i nte n de d. 
Perf or ma nce s pecificati o ns i ncl u de all clai ms ma de i n t he 
la beli n g of t he de vice. T he i nte n de d perf or ma nce of t he 
de vice refers t o t he i nte n de d use f or w hic h t he de vice is 
la bele d or mar kete d. 
N o n -seri o us A d verse E ve nt A E t hat d oes n ot meet t he criteria f or a S A E .
Ra n d o mize d S u bjects A n y  s u bject w h o is assi g ne d a ra n d o mize d treat me nt. 
Seri o us A d verse De vice 
Ef fect ( S A D E) A d verse de vice ef fect t hat has res ulte d i n a n y of t he 
c o nse q ue nces c haracteristic of a S A E .
Seri o us A d verse E ve nt 
( S A E) A E t h at le d t o a n y of t he f oll o wi n g: 
Deat h. 
A seri o us deteri orati o n i n t he healt h of t he s u bject t hat 
eit her res ulte d i n: 
a. a life -t hreate ni n g ill ness or i nj ur y .Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 8of 5 2 
N ote: Life -t hr e ate ni n g me a ns t h at t he 
i n divi d u al w as at i m me di ate risk of de at h fr o m 
t he eve nt as it occ urr e d, ie, it d oes n ot i ncl u de 
a n eve nt w hic h hy p ot hetic ally mi g ht h ave 
c a use d de at h h a d it occ urr e d i n a m or e sever e 
f or m. 
b. a n y  p ote ntiall y  si g ht -t hreate ni n g e ve nt or 
per ma ne nt i m pair me nt t o a b o d y str uct ure or a 
b o d y  f u ncti o n .
c. i n -patie nt h os pitalizati o n or pr ol o n ge d 
h os pitalizati o n. 
N ote: Pl a n ne d h os pit aliz ati o n f or a pr e- 
existi n g c o n diti o n, wit h o ut seri o us 
deteri or ati o n i n he alt h, is n ot c o nsi der e d a 
S A E . I n ge ner al, h os pit aliz ati o n si g nifies t h at 
t he i n divi d u al r e m ai ne d at t he h os pit al or 
e mer ge ncy w ar d f or o bserv ati o n a n d/ or 
tr e at me nt ( us u ally i nv olvi n g a n over ni g ht 
st ay) t h at w o ul d n ot h ave bee n a p pr o pri ate i n 
t he p hysici a n's office or a n o ut- p atie nt setti n g. 
C o m plic ati o ns t h at occ ur d uri n g 
h os pit aliz ati o n ar e A E s. If a c o m plic ati o n 
pr ol o n gs h os pit aliz ati o n or f ulfills a ny ot her 
seri o us criteri a, t he eve nt is seri o us. W he n i n 
d o u bt as t o w het her “ h os pit aliz ati o n ” 
occ urr e d, t he eve nt s h o ul d be c o nsi der e d 
seri o us. 
d. a me dical or s ur gical i nter ve nti o n t o pre ve nt 
a) or b). 
e. a n y  i n direct har m as a c o nse q ue nce of 
i nc orrect dia g n ostic test res ults w he n use d 
wit hi n ma n ufact urer ’s  i nstr ucti o ns f or use. 
Fetal distress, fetal deat h, or a c o n ge nital a b n or malit y  or 
birt h defect. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Page 9of 52
Refer to Section 1 1 for additional SAEs.
Significant No n-Serious 
Adverse EventIs a sy mptomatic, device -related, non -sight threatening AE
that warrants discontinuation of any contact lens wear for 
greater than or equal to 2 weeks.
Refer to Section 1 1 for additional Significant Non -Serious 
AEs.
Unanticipated Serious 
Adverse Device Ef fect 
(USADE)Serious adverse device effect which b y its nature, incidence, 
severit y or outcome has not been identified in the risk 
management file.
Use Error Act or omission of an act that results in a dif ferent medical 
device response than intended by  manufacturer or expected 
by user. Note: This definition includes slips, lapses, and 
mistakes. An unexpected physiological r esponse of the 
subject does not in its elf constitute a use err or
.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Page 10of 52
2LIST  OF ACRONYMS AND ABBREVIA TIONS
Table2–1 List of Acronyms and Abbr eviations Used in This Pr otocol
Abbreviation Definition
ADE Adverse device effect
AE Adverse event
BCVA Best corrected visual acuity
CFR Code of Federal Regulations
CRF Case report form
CSM Clinical site manager
CTT Clinical trial team
D Diopter(s)
D/C Discontinue
DD Daily  disposable
DD T2 Daily  Disposable T2 Soft Contact Lenses
DT1 DAILIES TOTAL1 Daily  Disposable Contact Lenses
DS Diopters sphere
eCRF Electronic case report form
EDC Electronic data capture
FDA US Food and Drug Administration
GCP Good Clinical Practice
GPCMS Global Product Complaint Management Sy stem
 
IB Investigator’s brochure
ICF Informed consent form
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
IEC Independent ethics committee
IP Investigational product
IRB Institutional review board
IRT Interactive response technology
ISO International Organization for Standardization
LCSM Lead clinical site manager
LID Lens identification 
LogMAR Logarithm of the minimum angle of resolution
mm Millimeter
MOP Manual of procedures
n Number
N/A Not applicable
O/R Over refraction
OU Both ey es
pt Point
SAE Serious adverse event
SADE Serious adverse device effect
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 11of 52
Abbreviation Definition
SiHy  Silicone hy drogel
SLE Slit-lamp examination
SOP Standard operating procedure
US / USA United States of America
USADE Unanticipated serious adverse device effect
USAN United States Adopted Name
USV Unscheduled visit
VA Visual acuity
vs Versus 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Page 12of 52
3PROTOCOL  SUMMAR Y
This will be a prospective, randomized ,controlled, 
double -masked, parallel- group clinical trial.
Approximately 6sites in the US will enroll approximately  99subjects. Subjects will be
randomized to wear either the test DD T2 lenses in both ey es or the control DT1 lenses in 
both ey es for 3 months. Approximately  66subjects will be assigned to wear the test lenses 
and 3 3the control lenses, following the 2:1 subject allocation ratio as recommended by  ISO 
11980:2012 and the US FDA 510(k) guidance document.
Subjects will be expected to attend 7 of
fice visits: Baseline, Dispense, 1-week follow -up, 2-
week follow -
up, 1- month follow - up, 2- month follow - upand 3 -month follow -up/Exit.
Following randomization a t the Baseline visit, study  lenses will be trial fit using the fitting set 
supplied by  the Sponsor , and the correct contact lens power for the individual subject will be
determined. The Sponsor will send investigational lenses for each subject to the site after 
receiving an order from the 
Investigator . Between the Baseline and Dispense visits, subjects 
will be allowed to wear their habitual lenses. Biomicroscop y will be repeated at the Dispense 
visit.
 
 
 
 
 
 
Investigational 
product typeDevice
Study type Interventional
Investigational 
productsTestProduct : DD T2 soft contact lenses
Control Product : DT1 (delefilcon A) soft contact lenses
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Pa ge 1 3 of 5 2 
P ur p ose a n d 
r ati o n ale T he p ur p ose of t his cli nical trial is t o e val uate t he perf or ma nce of 
t he i n vesti gati o nal D D T 2 le ns c o m pare d t o t he c o m mercial l y  
a vaila ble D T 1 le ns , b y  assessi n g vis ual ac uit y  as t he pri mar y  
varia ble. 
Objecti ves T he pri mar y  o bjecti ve is t o de m o nstrate effecti ve ness a n d safet y of 
t he D D T 2 s oft c o ntact le ns w he n w or n f or dail y dis p osa ble wear 
as c o m pare d t o D T 1 s oft c o ntact le ns. 
E n d p oi nt s Pri mar y  Effecti ve ness 
Dista nce V A ( S nelle n) 
Safet y 
A E s
De vice deficie ncies 
Bi o micr osc o p y
Assess me nt s Effecti ve ness 
V A  ( S nelle n dista nce) wit h I P

Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 1 4 of 5 2 
  
  





Safet y 
A E s 
De vice deficie ncies 
Bi o micr osc o p y
St u d y Desi g n T his will be a pr os pecti ve, ra n d o mize d, stratifie d, c o ntr olle d, 
d o u ble -mas ke d, parallel -gr o u p cli nical trial. S u bject partici pati o n 
i n t he st u d y  will be a p pr o xi matel y  1 5 wee ks wit h a p pr o xi matel y  3 
m o nt hs of e x p os ure t o I P. 
S u bject p o p ul ati o n V ol u nteer s u b jects a ge d 1 8 or o ver w h o are s oft c o ntact le ns 
wearers, e xcl u di n g D T 1 ha bit ual wearers, ha ve at least 3 m o nt hs 
of c o ntact le ns weari n g e x perie nce, a n d w h o wear t heir ha bit ual 
le nses at least 5 da y s per wee k a n d at least 8 h o urs per da y . 
S u bjects m ust re q uire c o ntact le nses i n a p o wer ra n ge fr o m - 1. 0 0 
t o - 6. 0 0 D S.  
 Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 1 5 of 5 2 
Ke y i ncl usi o n 
criteri a 
( See Secti o n 8. 1 f or a 
c o m plete list of 
i ncl usi o n criteria) S uccessf ul wear of s p herical s oft c o ntact le nses f or dista nce 
c orrecti o n i n b ot h e y es d uri n g t he past 3 m o nt hs f or a 
mi ni m u m of 5 da y s per wee k a n d 8 h o urs per da y .
Best c orrecte d V A 2 0/ 2 5 or better i n eac h e y e.
Ke y e xcl usi o n 
criteri a 
( See Secti o n 8. 2 f or a 
c o m plete list of 
e xcl usi o n criteria) A n y  c urre nt or pri or wear e x perie nce wit h D T 1 le nses. 
We ari n g ha bit ual c o ntact le nses i n a n e xte n de d wear m o dalit y 
(r o uti nel y  slee pi n g i n le nses f or at least 1 ni g ht per wee k) o ver 
t he last 3 m o nt hs pri or t o e nr oll me nt. 
D at a a n al ysis a n d 
s a m ple size 
j ustific ati o n I n a d here nce t o t he re p orti n g f or mat as s pecifie d i n t he I S O a n d 
F D A 5 1 0( k) g ui da nce d oc u me nts, effecti ve ness a n d safet y data 
will be prese nte d se paratel y  base d u p o n s u bject st u d y  stat us of 
C o m plete d or Disc o nti n ue d. 
 
 
 
 
 
Sa m ple size is base d u p o n I S O a n d F D A 5 1 0( k) re q uire me nts a n d 
rec o m me n dati o ns of at least 5 0 s u bjects i n t he Test gr o u p , i n a 2: 1 
Test t o C o ntr ol rati o. 
Ke y w or ds D D T 2, D T 1, dail y dis p osa ble , re gistrati o n 
Ass oci ate d m ateri als L u bricati o n/re -wetti n g dr o ps pr o vi de d b y  A lc o n will be per mitte d 
as nee de d. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 1 6 of 5 2 
Ta ble 3 – 1 Sc he d ule of St u d y Pr oce d ur es a n d Assess me nts 
Pr oce d ure/ 
Assess me nt Visit 1, 
B aseli ne/ 
Scree ni n g 
( D a y 0)Visit 2, 
Dis pe nse 
st u d y 
le nses Visit 3, 
Wee k 1 
f oll o w -
u p Visit 4, 
Wee k 2 
f oll o w -
u p Visit 5, 
1- m o nt h 
f oll o w -
u p Visit 6, 
2- m o nt h 
f oll o w -
u p Visit 7, 
3- m o nt h 
f oll o w -
u p/ e xit U S V 
U p t o 
4da ys 
after le ns 
or der 
( Da y  1 
of le ns 
wear) 7 da ys 
(- 1/ + 2 
da ys) 
fr o m t he 
Dis pe nse 
visit 1 5 da ys 
(- 1/ + 3 
da ys) 
fr o m t he 
Dis pe nse 
visit 3 0 da ys 
(- 2 da ys 
/ + 5 da ys) 
fr o m t he 
Dis pe nse 
visit 6 0 da ys 
(- 2 da ys 
/ + 5 da ys) 
fr o m t he 
Dis pe nse 
visit 9 5 da ys 
(- 2 da ys 
/ + 5 da ys) 
fr o m t he 
Dis pe nse 
visit 
I nf or me d C o nse nt  - - - - - - -
D e m o gra p hics  - - - - - - -
Me dical Hist or y  - - - - - - -
C o nc o mita nt 
Me dicati o ns              ()
I ncl usi o n/ 
E xcl usi o n  - - - - - - -
Ha bit ual le ns 
i nf or mati o n 
( bra n d / 
ma n ufact urer, 
m o dalit y, p o w er , 
wear s uccess )  - - - - - - -
V A w/ ha bit ual 
c orrecti o n 
( S nelle n dista nce)    - - - -  ()
Bi o micr osc o p y              ()
Or der s u bject’s 
st u d y le nses  - - - - - - -
Dis pe nse or 
pr o visi o n of st u d y 
le nses -  - -    - ()
V A w/ st u d y 
le nses ( S nelle n 
dista nce)              ()Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 1 7 of 5 2 
Pr oce d ure/ 
Assess me nt Visit 1, 
B aseli ne/ 
Scree ni n g 
( D a y 0) Visit 2, 
Dis pe nse 
st u d y 
le nses Visit 3, 
Wee k 1 
f oll o w -
u p Visit 4, 
Wee k 2 
f oll o w -
u p Visit 5, 
1- m o nt h 
f oll o w -
u p Visit 6, 
2- m o nt h 
f oll o w -
u p Visit 7, 
3- m o nt h 
f oll o w -
u p/ e xit U S V 
U p t o 
4da ys 
after le ns 
or der 
( Da y  1 
of le ns 
wear) 7 da ys 
(- 1/ + 2 
da ys) 
fr o m t he 
Dis pe nse 
visit 1 5 da ys 
(- 1/ + 3 
da ys) 
fr o m t he 
Dis pe nse 
visit 3 0 da ys 
(- 2 da ys 
/ + 5 da ys) 
fr o m t he 
Dis pe nse 
visit 6 0 da ys 
(- 2 da ys 
/ + 5 da ys) 
fr o m t he 
Dis pe nse 
visit 9 5 da ys 
(- 2 da ys 
/ + 5 da ys) 
fr o m t he 
Dis pe nse 
visit 
A E s              ()
De vice 
deficie ncies              ()
E xit F or m () ( ) ( ) ( ) ( ) ( ) ( ) ( )
() assess me nt perf or me d as necessar y, e g, decrease of vis ual ac uit y  b y  2 li nes or m ore wit h i n vesti gati o nal pr o d ucts. 
U S V = U nsc he d ule d Visit 
ǂAlc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
 
 
 
Page 18of 52
4PROTOCOL  AMENDMENTS
Modification of the protocol is prohibited without prior written agreement in the form of a 
protocol amendment. All amendments must be created b y the Study Sponsor and must be 
approved b y the IRB/IEC and global and regional Health Authorities, as applicabl e,prior to 
implementation except when required to mitigate immediate safet y risks or when the changes 
involve only  logistical or administrative revisions. 
Amendments may  necessitate that the informed consent and other study -related material be 
revised. I f the consent form is revised, all subjects currentl y enrolled in the study  must sign 
the approved, revised informed consent (re-consent) , as required b y the IRB/IEC.
4.1 Amendments
There are no amendments. This is the first version of the protocol.
5INTRODUCTI ON
5.1 Rationale and Backgr ound
Daily  disposable (DD) lenses are worn for a full day , during waking hours, and then 
discarded after usage. This ty pe of contact lens eliminate sthe requirement for lens cleaning 
and disinfection and hasbeen shown to have higher compliance rates with lens replacement 
schedules compared to other lens wearing modalities (Dumbleton 2009) . Silicone hydrogel 
contact lenses provide superior ox ygen transmissibility over contact lenses made with 
conventional materials.
A new DD SiHy  lens, known here as DD T2, has been developed that combines high oxy gen 
transmissibility  with a low modulus of elasticity .
In this clinical trial, the performance of the investigational DD T2 lens will be compared to 
the commerciall y available DT1 (delefilco n A) lens in a parallel -group design with 3 months 
of exposure. The intended use of thiscontact lens is for vision correction. Therefore, the 
objective measurement of VAis planned as the primary  variable for the comparison with the 
DT1 lens.  
 
 
 
 The recommendations of ISO 11980:2012 and FDA  (510(k)) 
Guidance Document for Daily  Wear Contact Lenses
in regard to variables to assess were 
considered.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 19of 52
5.2 Purpose of the Study
The purpose of this clinical trial is to evaluate the performance of the investigational DD T2 
lens compared to the commercial ly available DT1 lens, by assessing VAas the primary  
variable. The study  is designed to fo llow the 2:1 subject allocation ratio as recommended b y 
ISO 1 1980:2012 and the US FDA 510(k) guidance document .At the end of the study , a 
clinical study  report will be prepared in accordance with applicable regulatory  requirements 
and standards.
There are no immediate plans to submit the results of this study  for publication; however , the 
results may  be of fered for publication if they  are of scientific interest, or if the results relate to 
a product that is subsequently  approved or cleared for marketing.
5.3 Risk s and Benefits
Contact lenses may  offer improved peripheral vision and the convenience of not wearing 
spectacles. Material properties and design characteristics of DD T2 are features consistent 
with successful contact lens wear . Based upon nonclinical testing and documented rationale 
for applicabilit y of test results, DD T2 are assessed to be non- toxic and biocompatible for 
on-eye use. 
DT1 lenses are for daily  wear use under a DD wear modality ; further details on any  known 
potential risks and benefits can be found in the package insert.
DD T2 and DT1 are not intended for use with a cleaning/disinfecting solution, and the 
biocompatibility  with lens care solutions and an y associated clinical ef fects are unknown. 
A summary  of the known potential risks and benefits associated with DD T2 can be found in 
the IB. Risks are minimized by  compliance with the eligibility  criteria and study  procedures, 
and through close supervision by  a licensed clinician during exposure to the study  lenses. The 
potential harms ass
ociated with on -eye exposure to the new lens materials include toxicity  
response, blurred vision, and ocular discomfort. In general, the risks with DD T2 are 
anticipated to be similar to other marketed DD soft contact lenses.
There may  also be unknown risks with the use of DD T2 . Risksto subjects in this clinical 
study  will be minimized by compliance with the eligibility  criteria and study  procedures, 
clinical oversight ,andmonitoring . Site personnel will educate subjects on proper h ygiene and 
lens handling, and compliance with the use of contact lenses according to the protocol. 
Subjects should be instructed not to wear contact lenses while sleeping or swimming due to 
increased risk of infection . Site personnel should advise 
the subjects to remove contact lenses 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Page 20of 52
and return for prompt follow -up of s ymptoms such as ocular discomfort, foreign body  
sensation, excessive tearing, vision changes, or h yperemia. 
Refer to the IBfor additional information. 
6STUDY  OBJECTIVES
6.1 Primary Objective
The primary  objective is to demonstrate the ef fectiveness and safet yof the DD T2 soft 
contact lens when worn for daily  disposable wear as compared to theDT1 soft contact lens. 
6.2 Secondary Objective
Not applicable.
6.4 Safety Objective(s)
Safety  endpoints are as follows:
Table6–2 Safety Objective(s)
Objective(s) Endpoint(s)
To assess duty of care and demonstration of 
safet y.AEs
Device Deficiencies
Biomicroscop y
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 21of 52
7INVESTIGA TIONAL  PLAN
7.1 Study Design
This will be a prospective, randomized,  controlled, double -masked, parallel -group 
clinical trial.
Approximately  6sites in the US will enroll approximately  99 subjects and with 
approximately  15
-18 subjects per site. Subjects will be randomized to wear either the test DD 
T2 lenses in both ey es or the co ntrol DT1 lenses in both ey es.
Subjects will be expected to attend 7 of fice visits. The total expected duration of the subject’ s 
participation is approximately  3 months. 
Thestudy  is expected to take approximately  4 months for completion. The study  outline is 
provided in Figure 7-1(below):
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 22 of 52
Figur e 7–1 Flowchart of Study Visits
7.2 Rationale for Study Design 
In this clinical trial, the performance of the investigational DD T2 lens will be compared to 
the commerciall y available DT1 (delefilco n A) lens in a double -masked, parallel -group 
design with approximately  3 months of exposure. The study  is designed following the 
recommendations for registration from I SO 1 1980:2012 and the US FDA  510(k) guidance 
document.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Page 23of 52
7.3 Rationale for Duration of Treatme nt/Follow-Up
The duration of exposure as well as the schedule of follow- up visits follow the recommended 
guidance from I SO 1 1980:2012 and the US FDA 510(k) guidance document.
7.4 Rationale for Choice of Control Product
DT1 contact lenses were chosen as the control product because th is lens is a proper predicate 
device to compare to DD T2 in regards to effectiveness and safet y. Both DD T2 and DT1 are 
silicone hy drogel lenses and are to be prescribed for single use, daily  disposable wear . The 
DT1 spherical sof t contact lenses are indicated for the optical correction of refractive 
ametropia (m yopia and hyperopia) in phakic or aphakic persons with non -diseased ey es. The 
lenses are not intended to be cleaned or disinfected and should be discarded after a single us e.
7.5 Data Monitoring Committee
Not applicable.
8STUDY  POPULA TION
The study  population consists of adult male and female subjects (age d 18 or over ), with non -
diseased ey es, who require optical correction for refractive ametropia.  
 
 
The intended stud y population consists of v olunteer subjects aged 18 or over who are soft 
contact lens wearers, excluding DT1 habitual wearers, who have at least 3 months of contact 
lens wearing experience, and who wear their habitual lenses at least 5 day s per week and at 
least 8 hours per day . Subjects must require contact lenses in a power range from -1.00 
to -6.00 DS.  
 
8.1 Inclusion Criteria
Written informed consent must be obtained before any study  specific assessment is 
performed. Upon signing informed consent, the subject is considered enrolled in the study .
Subjects eligible for inclusion in this study  must fulfill allof the following criteria:
1. Subject must be at least 18 y
ears of age and must be able to understand and sign an 
IRB/IEC approved informed c onsent f orm. 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 24of 52
2. Willing and able to attend all scheduled stud y visits as required per protocol.
3. Successful wear of spherical soft contact lenses for distance correction in both ey es 
during the past 3 months for a minimum of 5 day s per week and 8 hours per day .
4. Manifest cy linder ≤ 0.75 D in each ey e.
5. Best spectacle corrected visual acuity  20/25 or better in each ey e.
8.2 Exclusion C riteria
Subjects fulfilling anyof the following criteria are not eligible for participation in this study .
1. Any anterior segment infection, inflammation, or abnormality  or disease (including 
systemic) that contraindicates contact lens wear , as determined b y the Investigator .
2. Any use of s ystemic or ocular medications for which contact lens wear could be 
contraindicated, as determined by  the Investigator .
3. History  of ocular or intraocula r surgery , including refractive surgery and/or irregular 
cornea.
4.Biomicroscop y findings at baseline that are moderate (grade 3) or higher and/or 
corneal vascularization that is mild (grade 2) or higher .
5.Current or history  of pathologicall y dry eye in either ey e that, in the opinion of the 
Investigator , would preclude contact lens wear .
6.Current or history  of herpetic keratitis in either eye.
7.Eye injury  in either ey e within 12 weeks immediately  prior to enrollment for this 
trial.
8.Any curre nt or prior wear experience with DT1 lenses.
9.Wearing habitual contact lenses in an extended wear modality  (routinel y sleeping in 
lenses for at least 1 night per week) over the last 3 months prior to enrollment
10.History  of intolerance or hypersensitivity  to an y component of the study lenses.
11.Enrollment of site staf f or family /household members of the site staf f who are listed 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Pa ge 2 5 of 5 2 
o n t he st u d y  pers o n nel l o g as ha vi n g a r ole i n t he e xec uti o n of t his st u d y .
12.Partici pati o n of t he s u bject i n a cli nical trial wit hi n t he pre vi o us 3 0 da y s or c urre ntl y 
e nr olle d i n a n y cli nical trial. 
8. 3 Rescree ni n g of S u bjects 
Rescree ni n g of s u bjects is n ot all o we d i n t his st u d y. 
9T R E A T M E N T S A D MI NI S T E R E D 
9. 1 I n vesti g ati o n al Pr o d uct(s) 
Te st Pr o d uct: D D T 2 dail y dis p osa ble s oft c o ntact le nses 
C o ntr ol Pr o d uct: D T 1 ( delefilc o n A) dail y  dis p osa ble s oft c o ntact 
le nses 
Ta ble 9 – 1 Te st Pr o d uct 
Te st Pr o d uct D D T 2 dail y dis p osa ble s oft c o ntact le nses 
( LI D 0 0 6 8 4 1) 
Ma n ufact urer Alc o n La b orat ories, I nc. 
6 2 0 1 S o ut h Free wa y 
F ort W ort h, T e xas 7 6 1 3 4 - 2 0 9 9 
U S A 
I n dicati o n f or use 
a n d i nte n de d 
p ur p ose i n t he 
c urre nt st u d y T he i nte n de d use of t his c o ntact le ns is f or visi o n c orrecti o n. 
Pr o d uct descri pti o n 
a n d para meters 
a vaila ble f or t his 
st u d y Material: 
Wa ter c o nte nt: 5 1 % 
P o wer ra n ge: - 1. 0 0 D t o - 6. 0 0 D, 0. 2 5 D ste ps 
Base c ur ve ( m m): 8. 3 
Dia meter ( m m): 1 4. 2 
A d diti o nal details ca n be f o u n d i n t he I B. 
F or m ulati o n Silic o ne H y dr o gel. A d diti o nal details ca n be f o u n d i n t he I B f or D D 
T 2. 
Usa ge We ar: 
oDail y  W ear Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 2 6 of 5 2 
oBilateral 
Re place me nt peri o d: Dail y  Dis p osa ble 
E x p os ure: At least ~8 h o urs per da y a n d at least ~ 5 da y s per 
wee k o ver a 3 m o nt h e x p os ure peri o d. 
Le ns Care: N/ A 
A d diti o nal details ca n be f o u n d i n t he M O P  
N u m ber/ A m o u nt of 
pr o d uct t o be 
pr o vi de d t o t he 
s u bject A cart o n c o ntai ni n g ~ 4 0 le nses ( per e y e) will be pr o vi de d t o t he 
s u bject at t he f oll o wi n g st u d y  visits: 
Vi sit 2 ( Dis pe nse) 
Vi sit 5 ( 1 m o nt h f oll o w -u p) 
Vi sit 6 ( 2 m o nt h f oll o w - u p) 
Pac ka gi n g 
descri pti o n Blister f oil pac k 
La beli n g descri pti o n Le ns F oil la bel i ncl u des: 
-material na me or i de ntifier 
-base c ur ve 
-dia meter 
-ma n ufact uri n g pr ot oc ol n u m ber 
-pac ki n g s ol uti o n 
-p o wer 
-l ot n u m ber 
-e x pirati o n date 
-c o nte nt state me nt 
-i n vesti gati o nal de vice state me nt 
- S p o ns or i nf or mati o n 
Pr o vi de d i n b o xes of ~ 4 0 le nses per p o wer per b o x, i de ntifie d 
wit h t he f oll o wi n g: 
- a c ol or c o de d la bel stati n g t he pr ot oc ol n u m ber 
-material i de ntifier 
-p o wer 
-a n i n vesti gati o nal use o nl y state me nt 
-trac ki n g n u m ber 
St ora ge c o n diti o ns St ore d at r o o m te m perat ure. 
S u p pl y Fitti n g sets will be pr o vi de d b y  t he S p o ns or bef ore t he start of 
t he trial t o be use d d uri n g Visit 1. Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 2 7 of 5 2 
St u d y  le nses will be pr o vi de d t o t he site f or eac h s u bject as per 
t he i n vesti gat or’s or der f or m . T he site will dis pe nse t he st u d y  
le nses t o t he s u bject at Visit 2 a n d pr o vi de m o nt hl y  s u p plies at 
Visit 5 a n d 6. 
Ta ble 9–2 C o ntr ol Pr o d uct 
C o ntr ol Pr o d uct D AI LI E S T O T A L 1 
( LI D 0 0 6 9 6 1) 
Ma n ufact urer  Alc o n La b orat ories, I nc. 
6 2 0 1 S o ut h Free wa y 
F ort W ort h, Te xas 7 6 1 3 4- 2 0 9 9 
U S A 
I n dicati o n f or Use T he i nte n de d use of t his c o ntact le ns is f or visi o n c orrecti o n. 
Pr o d uct descri pti o n 
a n d para meters 
a vaila ble f or t his 
st u d y Material: delefilc o n A 
Water c o nte nt : 3 3 %
P o wer ra n ge: - 1. 0 0 D t o - 6. 0 0 D, 0. 2 5 D ste ps 
Base c ur ve ( m m) :8. 5 
Dia meter ( m m) : 1 4. 1 
F or m ulati o n Silic o ne H y dr o gel. A d diti o nal details ca n be f o u n d i n t he D T 1 
pac ka ge i nsert .
Usa ge Wear: 
oDail y  Wear 
oBilateral 
Re place me nt peri o d: Dail y  Dis p osa ble 
E x p os ure: At least ~8 h o urs per da y a n d at least ~ 5 da y s per 
wee k o ver a 3 m o nt h e x p os ure peri o d. 
Le ns Care: N/ A 
A d diti o nal details ca n be f o u n d i n t he M O P 
N u m ber/ A m o u nt of 
Pr o d uct t o be 
Pr o vi de d t o t he 
s u bject A cart o n c o ntai ni n g ~ 4 0 le nses ( per e y e) wil l be pr o vi de d t o t he 
s u bject at t he f oll o wi n g st u d y  visits: 
Visit 2 ( Dis pe nse) 
Visit 5 ( 1 m o nt h f oll o w - u p) 
Visit 6 ( 2 m o nt h f oll o w - u p) Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pa ge 2 8 of 5 2 
Pac ka gi n g 
descri pti o n C o ntr ol pr o d uct pac ka gi n g is i de ntical t o Test pr o d uct, see 
Ta ble 9- 1 f or details. 
La beli n g descri pti o n Le ns F oil la bel i ncl u des: 
-material na me or i de ntifier 
-base c ur ve 
-dia meter 
-pac ki n g s ol uti o n 
-p o wer 
-l ot n u m ber 
-e x pirati o n date 
-c o nte nt state me nt 
- i n vesti gati o nal de vice state me nt 
- S p o ns or i nf or mati o n 
Pr o vi de d i n b o xes of ~ 4 0 le nses per p o wer per b o x, i de ntifie d 
wit h t he f oll o wi n g: 
- a c ol or c o de d la bel stati n g t he pr ot oc ol n u m ber 
-material i de ntifier 
-p o wer 
-a n i n vesti gati o nal use o nl y state me nt 
St ora ge c o n diti o ns St ore d at r o o m te m perat ure. 
S u p pl y Fitti n g sets will be pr o vi de d b y t he S p o ns or bef ore t he start of 
t he trial t o be use d d uri n g Visit 1. 
St u d y  le nses will be pr o vi de d t o t he site f or eac h s u bject as per 
t he i n vesti gat or’s or der f or m . T he site will dis pe nse t he st u d y  
le nses t o t he s u bject at Visit 2 a n d pr o vi de m o nt hl y  s u p plies at 
Visit 5 a n d 6. 
9. 2 Ot her Me dic al De vice or Me dic ati o n S pecifie d f or Use Duri n g t he 
St u d y Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
D uri n g t he cli nical st u d y S p o ns or pr o vi de d re wetti n g dr o ps ma y  be use d, if necessar y .  
Page 29of 52
9.3 Treatment Assignment / Randomization
Subjects will be randomized in a 2:1 ratio to receive either DD T2 or DT1 soft contact lenses , 
respectivel y. 
 
Only  after signing the ICF , a subject will be assigned a subject number by  the electronic data 
capture s ystem. 
A randomization list will be generated using a validated sy stem that automates the random 
assignment of treatment arms to randomization numbers in the specified ratio  
. Subjects will be assigned treatment according to the randomization list 
uploaded in the iMedidata BALANCE s ystem. The randomization list will be generated and 
maintained by the Study  Sponsor .
At V isit 1, all eligi ble subjects will be randomized via the EDC/I RT integration sy stem to one 
of the treatment arms. The Investigator or delegate will access the respective system after 
confirming that the subject meets all the eligibility  criteria. A randomization number will be 
automatically  assigned to the subject according to the subject randomization list but will not 
be communicated to the site user . The EDC/IR T integration sy stem will inform the site user 
of the treatment assignment 
to be dispensed to the subject.
9.4 Treatment masking
This study  is double -masked, with subjects randomized to use DD T2 or DT1 soft contact 
lenses forthe duration of the 3-month treatment period.
Table9–3 Unmasked Individuals Associated with the Study
Unma sked Individual Extent of Unmasking Rationale
Unmasked Study  
Coordinator (s)The Unmasked Stud y 
Coordinator (s)will manage IP 
inventory , as well as IP 
administration. This individual 
will have access to I P supply , 
accountability  logs, and other 
documents or supplies 
pertaining to IP. The 
unmasked coordinator will 
also assist with device The Unmasked Stud y 
Coordinator (s)will be 
unmasked to allow for 
processing of IP shipment, 
storage ,and dispensing, as 
well as accountability  for all 
IP.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Page 30of 52
Unma sked Individual Extent of Unmasking Rationale
deficiency  and adverse event 
reporting.
LCSM The L CSM will have access to 
IP suppl y, accountability logs, 
and other documents or 
supplies pertaining to IP . This 
individual assists with masked 
and unmasked data reviews .The L CSM will be unmasked 
to allow for oversight of the 
CSM, in conjunction with all 
IP accountability  tasks.
CSM CSM will have access to IP 
supply , accountability  logs, 
and other documents or 
supplies pertaining to IP 
accountability .This individual 
monitors unmasked and 
masked stud y data.The CSM will be unmasked 
to allow for performance of 
IP accountability , 
management of device 
deficiencies and related AE 
lens returns, and an y other IP 
related tasks.
Unmasked Data 
Manager(s)The Unmasked Data 
Manager (s)will have access to 
restri cted fields in RAVE that 
would contain unmasking 
data.The Unmasked Data 
Manager (s)will be unmasked 
to allow for review of all 
restricted data.
IRT Manager The I RT manager will be 
unmasked to allow for s ystem 
programming, testing, and to 
allow for technical oversight 
of the sy stem.The I RT manager is 
unmasked to all aspects of the 
trial for s ystem development 
purposes.
Randomization Specialist The Randomization Specialist 
will be unmasked to allow for 
generation of the 
randomization list and 
uploading of that list into the 
IRT s ystem.  Generates and therefore has 
full knowledge of treatment 
codes but otherwise is 
operationall y not associated 
with the CTT or an y decision-
making aspects related to 
clinical trial design, 
execution, or reporting .
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Pa ge 3 1 of 5 2 
T his le vel of mas ki n g will be mai ntai ne d t hr o u g h o ut t he c o n d uct of t he st u d y . U n mas ki n g 
will occ ur o nl y  after all pla n ne d st u d y  data ha ve bee n vali date d a n d t he data base l oc ke d. 
Mas ke d st u d y  pers o n nel m ust a v oi d see ki n g i nf or mati o n t hat ma y  c o m pr o mise mas ki n g. 
U n mas ke d st u d y  pers o n nel m ust n ot disse mi nate i nf or mati o n t hat is p ote ntiall y  u n mas ki n g t o 
a n y  mas ke d pers o n nel. T he mas ke d a n d u n mas ke d site pers o n nel m ust c o or di nate all st u d y  
acti vities as necessar y  t o pr otect mas ki n g a n d mi ni mize bias d uri n g t he st u d y . 
I n t he e ve nt of a me dical e mer ge nc y w here t he k n o wle d ge of s u bject treat me nt is re q uire d, a n 
i n di vi d ual I n vesti gat or will ha ve t he a bilit y  t o u n m as k t he treat me nt assi g n me nt f or a s pecific 
s u bject after c o ntacti n g a n a p pr o priate St u d y S p o ns or re prese ntati ve if ti me all o ws. 
U n mas ki n g m ust be d o ne acc or di n g t o t he i nstr ucti o ns pr o vi de d f or t he st u d y I R T s y ste m. 
9. 5 Acc o u nt a bilit y Pr oce d ures 
U p o n recei pt of t he I Ps, t he I n vesti gat or or dele gate m ust c o n d uct a n i n ve nt or y . D uri n g t he 
st u d y , u n mas ke d desi g nate d st u d y  staff m ust pr o vi de t he I Ps t o t he s u bjects i n acc or da nce 
wit h t heir ra n d o mizati o n assi g n me nt. T hr o u g h o ut t he st u d y , t he I n vesti gat or or dele gate m ust 
mai ntai n rec or ds of I P  dis pe nsati o n a n d c ollecti o n f or eac h s u bject. T his rec or d m ust be ma de 
a vaila ble t o t he st u d y m o nit or f or t he p ur p oses of verif yi n g t he acc o u nti n g of I P  s u p plies. 
A n y  discre pa ncies a n d/ or deficie ncies bet wee n t he o bser ve d dis p o siti o n a n d t he writte n 
acc o u nt m ust be rec or de d al o n g wit h a n e x pla nati o n. All I Ps se nt t o t he I n vesti gat or m ust be 
acc o u nte d f or b y St u d y S p o ns or pers o n nel, a n d i n n o case be use d i n a n u na ut h orize d 
sit uati o n. 
It is t he I n vesti gat or ’s  res p o nsi bilit y  t o e n s ure t hat: 
All st u d y  pr o d ucts are acc o u nte d f or a n d n ot use d i n a n y  u na ut h orize d ma n ner 
All use d f oils a n d u n use d s u p plies are ret ur ne d b y eac h s u bject 
All u n use d pr o d ucts are a vaila ble f or ret ur n t o t he St u d y  S p o ns or , as directe d 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
A n y  st u d y  le nses ass ociat e d wit h a de vice deficie nc y  or wit h a n y  pr o d uct -relate d A E (ie, 
A D E or S A D E) are ret ur ne d t o t he St u d y  S p o ns or f or i n vesti gati o n , u n less ot her wise 
directe d b y t he S p o ns or . Refer t o Secti o n 1 1 of t his pr ot oc ol f or a d diti o nal i nf or mati o n o n 
t he re p orti n g of de vice deficie ncies a n d A Es a n d t he ret ur n of st u d y pr o d ucts ass ociate d 
wit h t hese e ve nts. 
T he I n vesti gat or is res p o nsi ble f or pr o per dis p ositi o n of all u n use d I Ps at t he c o ncl usi o n of 
t he st u d y , acc or di n g t o t he i nstr ucti o ns pr o vi de d i n t he M O P .
Pa ge 3 2 of 5 2 
9. 6 C h a n ges t o c o nc o mit a nt me dic ati o ns, tr e at me nts/ pr oce d ur es 
C ha n ges i n c o nc o mita nt treat me nts after Vi sit 1 are n ot all o we d u nless nee de d f or t he pr o per 
me dical care a n d treat me nt of t he s u bject f or a s pecific me dical c o n diti o n. 
After t he s u bject is e nr olle d i nt o t he st u d y , t he I n vesti gat or m ust i nstr uct t he s u bject t o n otif y  
t he st u d y  site a b o ut: 
A n y  ne w me dicati o ns 
Alterati o ns i n d ose or d ose sc he d ules f or c urre nt me dicati o ns, 
A n y  me dical pr oce d ure or h os pitalizati o n t hat occ urre d or is pla n ne d 
A n y  n o n- dr u g t he ra pies (i ncl u di n g p h y sical t hera p y  a n d bl o o d tra nsf usi o ns). 
T he I n vesti gat or m ust d oc u me nt t his i nf or mati o n i n t he s u bject’ s case hist or y  s o urce 
d oc u me nts. 
1 0 S T U D Y  P R O C E D U R E S A N D A S S E S S M E N T S 
S u bjects will be e x pecte d t o atte n d 7 of fice visits , as s h o w n i n T a ble 1 0 - 1 : 
Ta ble 1 0 - 1 St u d y Vi sits 
Vi sit 
Vi sit 1: Baseli ne/ Scree ni n g ( Da y  0 )
Vi sit 2: Dis pe nse st u d y  le nses ( Da y  1) 
Vi sit 3: We e k 1 f oll o w - u p 
Vi sit 4: We e k 2 f oll o w - u p 
Vi sit 5: 1 -m o nt h f oll o w - u p 
Vi sit 6: 2 -m o nt h f oll o w - u p 
Vi sit 7: 3 -m o nt h f oll o w -u p/e xit Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
U nsc he d ule d V isits a n d Earl y Te r mi nati o n Vi sits are all o we d , if necessar y .
At t he Baseli ne visit, st u d y  le nses will be trial fit usi n g t he fitti n g set s u p plie d b y  t he S p o ns or , 
a n d t he c orrect c o ntact le ns p o wer f or t he i n di vi d ual s u bject will be deter mi ne d. T he S p o ns or 
will se n d i n ves ti gati o nal le nses f or eac h s u bject t o t he site after recei vi n g a n or der fr o m t he 
In vesti gat or . Bet wee n t he Baseli ne a n d Dis pe nse visits, s u bjects will be all o we d t o wear t heir 
ha bit ual le nses. Bi o micr osc o p y  will be re peate d at t he Dis pe nse visit. 
Page 33of 52
 
 
 
 
 
 
10.1 Informed Consent and Screening
The Investigator or delegate must explain the purpose and nature of the study , and have the 
subject read, sign, and date the I RB/IEC -approved informed consent document. The subject 
must sign the I CF BEFORE any  study -specific procedures or assessments can be performed, 
including study -specific screening procedures. Additionally , have the individual obtaining 
consent from the subject and a witness, if applicable, sign and date the informed consent 
document. 
The Investigator or delegate must provide a cop y of the signed doc ument to the subject and 
place the original signed document in the subject’ s chart, or provide documentation as 
required b y local regulations.
10.2 Description of Study Procedures and Assessments
Detailed descriptions of assessments and procedures are provided in the MOP . The 
Investigator is responsible for ensuring responsibilities for all procedures and assessments are 
delegated to appropriately qualified site personnel.
10.2.1 Demographics
Obtain demographic information including age, race, ethnicity , and sex.
10.2.2 Medic al History
Collect medical history  information , including information on all medications used within the 
past 30 days. Include herbal therapies, vitamins, and all over -the-counter as well as 
prescription medications. Throughout the subject’ s participation, obtain information on any  
changes in medical health and/or the use of concomitant medications.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Pa ge 3 4 of 5 2 
1 0. 2. 3 I n vesti g ati o n al Pr o d uct c o m pli a nce 
Re vie w s u bject c o m plia nce wit h t he I P  usa ge a n d a dj u nct pr o d uct usa ge a n d c ollect all use d 
a n d u n use d st u d y  I Ps a n d ot her pr o d ucts t hat were dis pe nse d. 
1 0. 2. 4 A d verse E ve nt C ollecti o n: S afet y Assess me nt 
Assess a n d rec or d a n y A E s t hat are o bser ve d or re p orte d, i ncl u di n g t h ose ass ociate d wit h 
c ha n ges i n c o nc o mita nt me dicati o n d osi n g si nce t he pre vi o us visit. 
1 0. 2. 5 Slit -L a m p Bi o micr osc o p y: S afet y Assess me nt 
S L E of t he c or nea, iris/a nteri or c ha m ber ,a n d le ns m ust be perf or me d i n b ot h e yes bef ore 
i ns tillati o n of a n y  dia g n ostic e y e dr o ps. 
1 0. 2. 6 De vice Deficie ncies: S afet y Assess me nt 
Assess a n d rec or d a n y de vice deficie ncies t hat are re p orte d or o bser ve d, i ncl u di n g t h ose 
ass ociate d wit h c ha n ges i n c o nc o mita nt me dicati o n d osi n g si nce t he pre vi o us visit. 
Re q uire me nts f or re p orti n g de vice deficie ncies i n t he st u d y ca n be f o u n d i n Secti o n 1 1. 
1 0. 2. 7 A d diti o n al St u d y Assess me nt s: Effecti ve ness a n d S afet y 
Assess me nt s
T he f oll o wi n g are a d diti o nal st u d y  assess me nts. Refer t o t he M O P  f or f urt her details. 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
V A  ( S nelle n dista nce) wit h I P
Pa ge 3 5 of 5 2 
1 0. 3 U nsc he d ule d Vi sits 
If a s u bject visit occ urs bet w ee n a n y re g ularl y sc he d ule d visits ,t his visit m ust be d oc u me nte d 
as a n U nsc he d ule d V isit. D uri n g all u nsc he d ule d visits, t he I n vesti gat or m ust c o n d uct t he 
f oll o wi n g pr oce d ures: 
C ollect A E i nf or mati o n , as a p plica ble 
Rec or d c ha n ges i n me dical c o n diti o n or c o nc o mita nt me dicati o n 
C ollect De vice Deficie nc y  i nf or mati o n , as a p plica ble 
Assess a n d rec or d V As 
Perf or m bi o micr osc o p y (assess me nts wit h or wit h o ut le nses, as a p plica ble) 
T he I n vesti gat or ma y  perf or m a d diti o nal pr oce d ures f or pr o per dia g n osis a n d treat me nt of t he 
s u bject. T he I n vesti gat or m ust d oc u me nt t his i nf or mati o n i n t he s u bject’ s case hist or y  s o urce 
d oc u me nts. 
If d uri n g a n U nsc he d ule d V isit t he s u bject is disc o nti n ui n g t he I P or disc o nti n ui n g fr o m t he 
st u d y , t he I n vesti gat or m ust c o n d uct E xit pr oce d ures acc or di n g t o T a ble 3- 1 Sc he d ule of 
St u d y  Pr oce d ures a n d Assess me nts ,as p ossi ble .
1 0. 4 Disc o nti n ue d S u bjects 
1 0. 4. 1 Scree n F ail ures 
S u bjects w h o were e xcl u de d fr o m t he st u d y after si g ni n g t he i nf or me d c o nse nt, n ot meeti n g 
t he i ncl usi o n/e xcl usi o n criteria, a n d pri or t o ra n d o mizati o n t o pr o d uct/ dis pe nse of st u d y  
pr o d uct. 
T he I n vesti gat or m ust d oc u me nt t he reas o n f or scree n fail ure i n t he s u bject’ s case hist or y  
s o urce d oc u me nts. 
Su bject n u m bers m ust n ot be re- use d. 
1 0. 4. 2 Disc o nti n u ati o ns Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Disc o nti n ue d s u bjects are i n di vi d uals w h o v ol u ntaril y wit h dra w or are wit h dra w n fr o m t he 
st u d y  b y  t he I n vesti gat or after si g ni n g t he i nf or me d c o nse nt, i ncl u di n g scree n fail ures. 
S u bject n u m bers of disc o nti n ue d s u bjects m ust n ot be re -use d. 
Pa ge 3 6 of 5 2 
S u bject s ma y  disc o nti n ue fr o m st u d y  or st u d y  treat me nt at a n y  ti me f or a n y reas o n. S u bjects 
ma y  als o be disc o nti n ue d fr o m st u d y  treat me nt at a n y  ti me if, i n t he o pi ni o n of t he 
I n vesti gat or , c o nti n ue d treat me nt p oses a ris k t o t heir healt h. 
F or s u bjects disc o nti n u i n g fr o m t he st u d y , t he I n vesti gat or m ust c o m plete all E xit pr oce d ures 
acc or di n g t o T a ble 3- 1, Sc he d ule of St u d y Pr oce d ures a n d Assess me nts, if t he s u bject is 
willi n g a n d a ble, a n d if i n t he o pi ni o n of t he I n vesti gat or it is safe f or t he s u bject t o d o s o. 
T he I n vesti gat or m ust d oc u me nt t he reas o n f or st u d y  or treat me nt disc o nti n uati o n i n t he 
s u bject’ s case hist or y  s o urce d oc u me nts. 
To  e ns ure t he safet y of all s u bjects w h o disc o nti n ue earl y,  I n vesti gat ors m ust assess eac h 
s u bject a n d, if necessar y , a d vise t h e m of a n y t hera pies a n d/ or me dical pr oce d ures t hat ma y  be 
nee de d t o mai ntai n t heir healt h. 
1 0. 4. 3 Sc he d ule of Pr oce d ures a n d Assess me nts f or S u bjects Disc o nti n ue d 
fr o m I n vesti g ati o n al Pr o d uct 
Ot her t ha n scree n fail ures, i f a s u bject disc o nti n ues fr o m t he st u d y  t he s u bject s h o ul d u n der g o 
a n Earl y E xit visit .Refer t o T a ble 3 -1 Sc he d ule of St u d y  Pr oce d ures a n d Assess me nts. 
1 0. 5 Cli nic al St u d y Te r mi n ati o n 
T he St u d y  S p o ns or reser ves t he ri g ht t o cl ose t he i n vesti gati o nal site or ter mi nate t he st u d y  i n 
its e ntiret y  at a n y  ti me. 
If t he cli nical st u d y is pre mat urel y ter mi nate d or s us pe n de d b y t he St u d y S p o ns or: 
T he St u d y  S p o ns or m ust: 
oI m me diatel y  n otif y  t he I n vesti gat or(s) a n d s u bse q ue ntl y  pr o vi de 
i nstr ucti o ns f or st u d y  ter mi nati o n. 
oI n f or m t he I n vesti gat or a n d t he re g ulat or y  a ut h orities of t he 
ter mi nati o n/s us pe nsi o n a n d t he reas o n(s) f or t he ter mi nati o n/s us pe nsi o n. 
T he I n vesti gat or m ust: 
oPr o m ptl y  n otif y  t he I R B/I E C of t he ter mi nati o n or s us pe nsi o n a n d of t he 
reas o ns. 
oAlc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Pr o vi de s u bject s wit h rec o m me n dati o ns f or p ost- st u d y  treat me nt o pti o ns 
as nee de d. 
Page 37of 52
The Investigator may  terminate the site’ s participation in the study  for reasonable cause.
10.5.1 Follow -up of subjects after study participation has ended 
Following this study , the subject will return to their eye care professional for their routine ey e 
care.
11ADVERSE EVENTS AND DEVICE DEFICIENCIES
11.1 General Information
An AE is an y untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory  findings) in subjects, users, or other persons, 
whether or not related to the investigational medical device (test article). Refer to the 
Glossary  of Terms and figures below for categories of AEs and SAEs.
Figur e11–1 Categorization of All Adverse Events
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Pa ge 3 8 of 5 2 
Fi g ur e11 - 2 C ate g oriz ati o n of All Seri o us A d verse E ve nts 
Seri o us A dverse Eve nts 
I n a d diti o n t o re p orti n g all A Es (seri o us a n d n o n -seri o us) meeti n g t he defi niti o ns, t he 
I n vesti gat or m ust re p ort a n y  occ urre nce of t he f oll o wi n g as a n S A E: 
A n oc ular i nfecti o n i ncl u di n g a pres u me d i nfecti o us ulcer wit h a n y of t he f oll o wi n g 
c haracteristics: 
oCe ntral or parace ntral l ocati o n 
oPe netrati o n of B o w ma n’ s me m bra ne 
oI n filtrates > 2 m m dia meter 
oIritis 
oI n crease i n i ntra oc ular press ure 
oC ult ure p ositi ve f or micr o or ga nis ms 
oI n creasi n g size or se verit y  at s u bse q ue nt visits 
A n y  ce ntral or parace ntral c or neal e ve nt (s uc h as ne o vasc ularizati o n) t hat res ults i n 
per ma ne nt o pacificati o n 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
H y p o p y o n 
Pa ge 3 9 of 5 2 
H y p he ma 
Ne o vasc ularizati o n wit hi n t he ce ntral 6 m m of t he c or nea 
Per ma ne nt visi o n l oss as defi ne d b y l oss of 2 or m ore li nes of B C V A fr o m e nr oll me nt 
visit t hat fails t o res ol ve 
U veitis ( a nteri or , i nter me diate, or p osteri or) 
C or neal a brasi o n affecti n g ≥ 5 0 % of c or neal s urface area 
Si g nific a nt N o n -Seri o us A dverse Eve nts 
A si g nifica nt n o n -seri o us A E is a de vice -relate d, n o n- si g ht t hreate ni n g A E t hat warra nts 
disc o nti n uati o n of a n y  c o ntact l e ns wear f or greater t ha n or e q ual t o 2 wee ks. I n a d diti o n, t he 
I n vesti gat or m ust re p ort a n y  occ urre nce of t he f oll o wi n g as a Si g nifica nt N o n - Seri o us 
A d verse E ve nt: 
Peri p heral n o n - pr o gressi ve n o n- i nfecti o us ulcers 
All s y m pt o matic c or neal i nfiltrati ve e ve n ts 
C or neal stai ni n g sc ore greater t ha n or e q ual t o Gra de 3 ( Refer t o M O P  f or gra di n g scales) 
[ Gra di n g scale is base d u p o n I S O 1 1 9 8 0: 2 0 1 2 u nless s pecifie d differe ntl y  i n M O P] 
Te m p orar y  visi o n l oss as defi ne d b y  l oss of 2 or m ore li nes of B C V A fr o m e nr oll me n t 
visit t hat persists f or 2 or m ore wee ks 
Ne o vasc ularizati o n sc ore greater t ha n or e q ual t o G ra de 2 ( Refer t o M O P  f or gra di n g 
scales) [ Gra di n g scale is base d u p o n I S O 1 1 9 8 0: 2 0 1 2 u nless s pecifie d differe ntl y  i n 
M O P] 
T he a b ove eve nts ar e b ase d u p o n t he c ate g ories pr ovi de d i n t he I S O 1 1 9 8 0 a n d t he U S F D A  
Pr e m arket N otific ati o n ( 5 1 0(k)) G ui d a nce D oc u me nt f or D aily W e ar C o nt act Le nses. 
Device Deficie ncies Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
A de vice deficie nc y  is i na de q uac y  of a me dical de vice wit h res pect t o its i de ntit y , q ualit y , 
d ura bilit y , rel ia bilit y , safet y , or perf or ma nce. A de vice deficie nc y  ma y  or ma y  n ot be 
ass ociate d wit h patie nt har m (ie, A D E or S A D E); h o we ver , n ot all A D Es or S A D Es are d ue 
t o a de vice deficie nc y . T he I n vesti gat or s h o ul d deter mi ne t he a p plica ble cate g or y liste d i n t he 
De vice Deficie nc y  e C R F f or t he i de ntifie d or s us pect de vice deficie nc y  a n d re p ort a n y patie nt 
har m se paratel y . E xa m ples of de vice deficie ncies i ncl u de t he f oll o wi n g: 
Pa ge 4 0 of 5 2 
Fail ure t o meet pr o d uct s pecificati o ns (e g, i nc orrect le ns p o wer/ dia meter/ base 
c ur ve/c ol or )
Le ns cl o u d y
Le ns s urface/e d ge defect 
To r n le ns d uri n g ha n dli n g/i n pac k 
Pac ka gi n g deficit (e g, mis la bele d pr o d uct )
S us pect pr o d uct c o nta mi nati o n 
Lac k of perf or ma nce 
1 1. 2 M o nit ori n g f or A d verse E ve nts 
At eac h visit, after t he s u bject has ha d t he o p p ort u nit y  t o s p o nta ne o usl y me nti o n a n y 
pr o ble ms, t he I n vesti gat or s h o ul d i n q uire a b o ut A Es b y  as ki n g t he sta n dar d q uesti o ns: 
“ Ha ve y o u ha d a n y healt h pr o ble ms si nce y o ur last st u d y  visit?” 
“ Ha ve t here bee n a n y c ha n ges i n t he me dici nes y o u ta ke si nce y o ur last st u d y  vi sit?” 
C ha n ges i n a ny pr ot oc ol -s pecific p ar a meters a n d/ or q uesti o n n air es e val uate d d uri n g t he 
st u d y  are t o be re vie we d b y  t he I n vesti gat or . A n y u nt o war d ( u nfa v ora ble a n d u ni nte n de d) 
c ha n ge i n a pr ot oc ol -s pecific p ar a meter or q uesti o n n air e r es p o nse t hat is c li nicall y  rele va nt, 
i n t he o pi ni o n of t he I n vesti gat or , is t o be re p orte d as a n A E. T hese cli nicall y  rele va nt 
c ha n ges will be re p orte d re gar dless of ca usalit y . 
1 1. 3 Pr oce d ures f or Rec or di n g a n d Re p orti n g 
A Es are c ollecte d fr o m t he ti me of i nf or me d c o nse nt .A n ypre -e xisti n g me dical c o n diti o ns or 
si g ns/s y m pt o ms prese nt i n a s u bject pri or t o t he start of t he st u d y  (ie, bef ore i nf or me d 
c o nse nt is si g ne d) are n ot c o nsi dere d A Es i n t he st u d y  a n d s h o ul d be rec or de d i n t he Me dical 
Hist or y  secti o n of t he e C R F .
I n a d diti o n, te m p orar y  le ns a ware ness or vis ual c ha n ges d uri n g t he fitti n g pr ocess are n ot 
c o nsi dere d A Es if t he I n vesti gat or assesses t hat t he s y m pt o m(s) ca n reas o na bl y  res ol ve wit hi n 
t he a ntici pate d a da ptati o n peri o d. 
A D Es or S A Es are d oc u me nte d o n t he Seri o us A dverse Eve nt a n d A dverse Device Effect 
e C R F wit hi n 2 4 h o urs of t he I n vesti gat or ’s  or site’ s a ware ness .
De vice deficie ncies are d oc u me nte d o n t he Device Deficie ncy Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
e C R F wit hi n 2 4 h o urs of 
t he I n vesti gat or ’s  or site’ s a ware ness .
Pa ge 4 1 of 5 2 
A pri nte d c o p y of t he c o m plet e d Seri o us A dverse Eve nt a n d A dverse Device Effect a n d/ or 
Device Deficie ncy e C R F m ust be i ncl u de d wit h pr o d uct ret ur ns. 
A d diti o nal rele va nt i nf or mati o n after i nitial re p orti n g m ust be e ntere d i nt o t he e C R F as 
s o o n as t he data bec o me a vaila ble. 
D oc u me nt a n yc ha n ges t o c o nc o mita nt me dicati o ns o n t he a p pr o priate e C R Fs. 
D oc u me nt all rele va nt i nf or mati o n fr o m Disc har ge S u m mar y , A ut o ps y  Re p ort, Certificate 
of Deat h ,etc, if a p plica ble, i n narrati ve secti o n of t he Seri o us A dverse Eve nt a n d A dverse 
Device Effect e C R F .
N ote: S h o ul d t he E D C s yste m bec o me n o n - o perati o nal, t he site m ust c o m plete t he 
a p pr o priate pa per Seri o us A dverse Eve nt a n d A dverse Device Effect a n d/ or Device Deficie ncy 
F or m. T he c o m plete d f or m is e maile d t o t he St u d y  S p o ns or at 
F T W . me dical _safet y @ alc o n.c o m acc or di n g t o t he ti meli nes o utli ne d a b o ve; h o we ver , t he 
re p orte d i nf or mati o n m ust be e ntere d i nt o t he E D C s y ste m o nce it bec o mes o perati o nal. 
A n y  A Es a n d de vice deficie ncies f or n o n -st u d y  mar kete d de vices/ pr o d ucts will be c o nsi dere d 
a n d pr ocesse d as s p o nta ne o us (f oll o wi n g t he p ost mar ket vi gila nce pr oce d ures) a n d s h o ul d be 
c o m m u nicate d t o t he de vice’s/ pr o d uct’s ma n ufact urer as per l ocal re q uire me nts. 
St u d y  S p o ns or re prese ntati ves ma y  be c o ntacte d f or a n y  pr ot oc ol relate d q uesti o n a n d t heir 
c o ntact i nf or mati o n is pr o vi de d i n t he M O P t hat acc o m pa nies t his pr ot oc ol. 
F urt her, de pe n di n g u p o n t he nat ure of t he A E or de vice deficie nc y  bei n g re p orte d, t he St u d y  
S p o ns or ma y  re q uest c o pies of a p plica ble p orti o ns of t he s u bject’s me dical rec or ds. T he 
I n vesti gat or m ust als o re p ort all A Es a n d de vice deficie ncies t hat c o ul d ha ve le d t o a S A D E 
acc or di n g t o t he re q uire me nts of re g ulat or y  a ut h orities or I R B/I E C. 
I nte nsit y a n d C a us alit y Assess me nts 
W here a p pr o priate, t he I n vesti gat or m ust assess t he i nte nsit y  (se verit y) of t he A E base d u p o n 
me dical j u d g me nt wit h c o nsi derati o n of a n y s u bjecti ve s y m pt o m(s), as defi ne d bel o w: 
I nte nsity ( Severity) Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Mil d A n A E is mil d if t he s u bject is a ware of b ut ca n easil y  t olerate t he si g n or 
s y m pt o m. 
M o derate A n A E is m o derate if t he si g n or s y m pt o m res ults i n disc o mf ort si g nifica nt 
e n o u g h t o ca use i nterfere nce wit h t he s u bject’ s us ual acti vities. 
Page 42of 52
Severe An AE is severe if the sign or sy mptom is incapacitating and results in the 
subject’ s inability  to work or engage in their usual activities.
For every  AE in the study , the Investigator must assess the causalit y (Related or Not Related 
to the medical device or study  procedure). An assessment of causality  will also be performed 
by Study  Sponsor utilizing the same definitions, as shown below:
Causality
Related An AE classified as related may  be either definitely  related or possibl y related 
where a direct cause and ef fect relationship with the medical device or study  
procedure has not been demonstrated, but there is a reasonable possibil ity that 
the AE was caused by  the medical device or stud y procedure.
Not Related An AE classified as not related may  either be definitely  unrelated or simply  
unlikely  to be related (ie, there are other more likely  causes for the AE).
The Study  Sponsor wil l assess the AEs and may  upgrade the Investigator ’s assessment of 
seriousness and/or causality . The Study  Sponsor will notify  the Investigator of an y AEs that 
areupgraded from non -serious to serious or from unrelated to related.
11.4 Return product analysis
Alcon products associated with device deficiencies and/or product related AEs should be 
returned and must include the Complaint # which will be provided by  Study  Sponsor after the 
case is entered in the Study  Sponsor ’s Global Product Complaint Management Sy stem 
(GPCMS).
11.5 Unmask ing of the Study Treatment
Masked information on the identity  of the assigned medical device should not be disclosed 
during the stud y. If the treatment code needs to be broken in the interest of subject safet y, the 
Investigator is encour aged to contact an appropriate Study  Sponsor representative prior to 
unmasking the information if there is suf ficient time. Dependent upon the individual 
circumstances (ie, medical emergency), the code may be broken prior to contact with the 
Study  Sponsor .The Study  Sponsor must be informed of all cases in which the code was 
broken and of the circumstances involved. Additionally , the Study  Sponsor may  be required 
to unmask the information in order to fulfill expedited regulatory  requirements.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Page 43of 52
11.6 Follow -Up of Subjects with Adverse Events 
The Investigator is responsible for adequate and safe medical care of subjects during the 
study  and for ensuring that appropriate medical care and relevant follow -up procedures are 
maintained after the study . 
The Investigator should provide the Study  Sponsor with any  new safet y information (which 
includes new AEs and changes to previousl y reported AEs) that may  affect the safet y 
evaluation of the device. For AEs that are unresolved/ ongoing at time of subject exit from 
study , any additional information received at follow -up should be documented in the eCRFs 
up to study  completion (ie, database lock). 
Any additional data received up to 1 month after subject discontinuation or exit must be 
documented and available upon the Study  Sponsor’s request. All complaints received after 
this time period will be considered and processed as spontaneous (following the postmarket 
vigilance procedures) and should be communicated to the medical device’s manufacturer as 
per local requirements.
TheInvestigator should also report complaints on non -Alcon products directly  to the 
manufacturer as per the manufacturer’s instructions or local regulatory  requirements
.
11.7 Pregnancy in the Clinical Study
Women of childbearing potential or women who are pregnant at the time of study  entry  are 
not excluded from participation. Pregnancy  should be included in the Medical History  section 
of the eCRF when a pregnant woman enters the study  or if a woman becomes p regnant 
during the stud y. Pregnancy  is not reportable as an AE; however , complications may  be 
reportable and will be decided on a case –by- case basis. 
12ANAL YSIS PLAN
Any deviations to the analy sis plan will be updated during the course of the study  as part of a 
protocol amendment or will be detailed in the clinical study  report.
All analy ses will be conducted according to the applicable statistical anal ysis plan.
12.1 Subject Evaluability
Final subject evaluability must be determined prior to breaking the code for masked treatment 
assignment and locking the database, based upon the Deviations and Evaluability  Plan.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Pa ge 4 4 of 5 2 
1 2. 2 A n al ysis Sets 
Fi ve a nal y sis sets will be defi ne d: 
a) All E nr olle d –all s u bjects si g ni n g t he inf or me d co nse nt for m 
b) E nr olle d Dis pe nse d –s u bjects/e y es fr o m All E nr olle d w h o ha ve bee n e x p ose d t o st u d y  
le nses 
c) E nr olle d N ot Dis pe nse d –s u bjects/e y es fr o m All E nr olle d w h o ha ve n ot bee n e x p ose d 
t o st u d y  le nses 
d) C o m plete d –E nr olle d Dis pe nse d s u bjects c o m pleti n g t he st u d y 
e) Disc o nti n ue d – E nr olle d Dis pe nse d w h o di d n ot c o m plete t he st u d y 
1 2. 3 De m o gr a p hic a n d B aseli ne C h ar acteristics 
De m o gra p hic i nf or mati o n,  
 a n d ha bit ual le ns i nf or mati o n will be prese nte d b y le ns gr o u p a n d o verall f or 
t he All E nr olle d set. 
 
1 2. 4 Effecti ve ness A n al yses 
F o r eac h of t he pri mar y  ef fecti ve ness e n d p oi nts, se parate s u m mar y  ta bles 
will be pre pare d f or t he C o m plete d a n d t he Disc o nti n ue d sets as f oll o ws: 
C o m plete d C o ntr ol (e y es/s u bjects) 
C o m plete d Te st (e y es/s u bjects) 
Disc o nti n ue d C o ntr ol (e yes/s u bj ects) 
Disc o nti n ue d T est (e y es/s u bjects) 
 
 
 
1 2. 4. 1 A n al ysis of Pri m ar y Effecti ve ness E n d p oi nt Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
T he pri mar y  o bjecti ve of t his st u d y  is t o de m o nstrate t he effecti ve ness a n d safet y of D D T 2 
c o m pare d t o D T 1. 
Pa ge 4 5 of 5 2 
T he pri mar y  e n d p oi nt is V A wit h st u d y  le nses, c ollecte d b y e ye .
1 2. 4. 1. 1 St atistic al H y p ot heses 
N o h y p ot hesis testi n g of t he pri mar y  ef fecti ve ness e n d p oi nt is pla n ne d. 
1 2. 4. 1. 2 A n al ysis Met h o ds 
S u m mar y  statistics will be pr o vi de d. 
A d diti o nall y , t he f oll o wi n g will be prese nte d: 
S hift ta ble c o m pari n g V A at dis pe nse vs s u bse q ue nt visits 
Fre q ue nc y  a n d perce nt f or V A  of 2 0/ 3 0 or better , fi nal V A  wit hi n 1 li ne of Dis pe nse , fi nal 
V A  w orse t ha n 1 li ne of Dis pe nse 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
Listi n g f or V A c ha n ges fr o m Dis pe nse of 2 or m ore li nes d uri n g t he st u d y 
Pa ge 4 6 of 5 2 
1 2. 5 H a n dli n g of Missi n g D at a 
All data o btai ne d i n e val ua ble s u bjects/e y es will be use d. N o i m p utati o n f or missi n g val ues 
will be carrie d o ut. 
I n ci de nce a n d reas o ns f or disc o nti n uati o n b y  le ns gr o u p will be ta b ulate d at eac h visit a n d 
o verall. 
1 2. 6 S afet y A n al ys es 
T he safet y e n d p oi nts are: 
A E s
De vice Deficie ncies 
Bi o micr osc o p y
T here are n o safet y h y p ot heses pla n ne d i n t his st u d y . T he f oc us of t he safet y a nal ys is will be 
a c o m pre he nsi ve descri pti ve assess me nt of occ urre nce of A E as well as t he ot her liste d 
para meters. 
Descri pti ve s u m maries (c o u nts a n d perce nta ges) f or oc ular a n d n o n oc ular A Es will be 
prese nte d b y M e dical Dicti o nar y  f or Re g ulat or y  A cti vities Preferre d T er ms, f or C o m plete d 
a n d Disc o nti n ue d sets. A listi n g c o ntai ni n g details of t he A Es will als o be pr o vi de d. 
Eac h bi o micr osc o p y para meter will be ta b ulate d b y its gra de, o n C o m plete d a n d 
Disc o nti n ue d sets. 
Fre q ue nc y  f or eac h de vice deficie nc y  cate g or y  will be prese nte d a n d a s u p p orti n g listi n g will 
be pr o vi de d. 
1 2. 7 I nteri m A n al yses a n d Re p orti n g Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
T here are n o pla ns t o c o n d uct a n i nteri m a nal ys is. 
Page 47of 52
13DATA HANDLING AND ADMINISTRA TIVE REQUIREMENTS
13.1 Subject C onfidentiality
The Investigator must ensure that the subject’ s anony mity is maintained throughout the 
course of the stud y. In particular , the Investigator must keep an enrollment log with 
confidential identify ing information that corresponds to the subject numbers and initials of 
each stud y participant. At the end of the clinical study , the Study  Sponsor will collect a copy  
of the enrollment log without any identifying subject information . All documents submitted 
to the Study  Sponsor will identify  the subjects exclusively  by number and demographic 
information. No other personally  identify ing information will be transmitted to the Study  
Sponsor .
The Study  Sponsor may  release anony mized study data to external researchers for purposes 
of future research directly  related to the study  objectives, or future research that is bey ond the 
scope of the current study objectives. The informed c onsent f orm explains this to study  
subjects. Anon ymization means that all identifiable information will be removed from the 
dataset and all links to the subjects in the study will be removed. Anon ymization of the data 
will maintain confidentiality  of the subjects who participate in the stud y so that they cannot 
be identified b y external researchers. The anon ymized data set will contain records from all 
of the subjects in the current study , but the anonymization process might change the data set 
in some ways, so external researchers will be informed that they  might not be able to 
duplicate some o f the results from this study .
13.2 Completion of Sour ce Documents and Case Report Forms
The nature and location of all source documents will be identified to ensure that original data 
required to complete the CRFs exist and are accessible for verification by  the site monitor , 
and all discrepancies shall be appropriately  documented via the query  resolution process. Site
monitors are appointed by the Stud y Sponsor and a re independent of stud y site staf f.
If electronic records are maintained, the method of verification must be determined in
advance of starting the study . 
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017

Pa ge 4 8 of 5 2 
At a mi ni m u m, s o urce d oc u me nts i ncl u de t he f oll o wi n g i nf or mati o n f or eac h s u bject: 
S u bject i de ntificati o n ( na me, se x, race/et h nicit y) 
D oc u me ntati o n of s u bject eli gi bilit y 
Date of i nf or me d c o nse nt 
Dates of visits 
D oc u me ntati o n t hat pr ot oc ol s pecific pr oce d ures were perf or me d 
Res ults of st u d y  para meters, as re q uire d b y t he pr ot oc ol 
I P  acc o u nta bili t y  rec or ds 
D oc u me ntati o n of A Es a n d ot her safet y para meters (if a p plica ble) 
Rec or ds re gar di n g me dical hist ories a n d t he use of c o nc o mita nt t hera pies pri or t o a n d 
d uri n g t he st u d y
Date of st u d y c o m pleti o n a n d reas o n f or earl y disc o nti n uati o n, if a p plica ble 
It is re q uire d t hat t he a ut h or of a n e ntr y  i n t he s o urce d oc u me nts be i de ntifia ble. Direct access 
t o s o urce d oc u me ntati o n ( me dical rec or ds) m ust be all o we d f or t he p ur p ose of verif y i n g t hat 
t he data rec or de d o n t he C R F are c o nsiste nt wit h t he ori gi nal s o ur ce data. 
O nl y  desi g nate d i n di vi d uals at t he site will c o m plete t he C R Fs. T he C R Fs m ust be c o m plete d 
at re g ular i nter vals f oll o wi n g t he cli nical st u d y  visit sc he d ule. I t is e x pecte d t hat all data 
re p orte d ha ve c orres p o n di n g e ntries i n t he s o urce d oc u me nts. T he Pri nci pal I n vesti gat or is 
res p o nsi ble f or re vie wi n g a n d certif y i n g t hat t he C R Fs are acc urate a n d c o m plete. T he o nl y 
s u bject i de ntifiers rec or de d o n t he C R Fs will be s u bject n u m ber , a n d s u bject de m o gra p hic 
i nf or mati o n. 
1 3. 3 D at a Re vie w a n d Cl arific ati o ns 
A re vie w of C R F data t o t he s u bject’ s s o urce data will be c o m plete d b y  t he site m o nit or t o 
e ns ure c o m plete ness a n d acc urac y . After t he C R Fs ha ve bee n c o m plete d, a d diti o nal data 
clarificati o ns a n d/ or a d diti o ns ma y  be nee de d as a res ult of t he data clea ni n g pr ocess. Data 
clarificati o ns are d oc u me nte d a n d are part of eac h s u bject’ s C R F .
1 3. 4 S p o ns or a n d M o nit ori n g Res p o nsi bilities Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
T he St u d y  S p o ns or will desi g nate a m o nit or t o c o n d uct t he a p pr o priate site visits at t he 
a p pr o priate i nter vals acc or di n g t o t he st u d y m o ni t ori n g pla n. T he cli nical i n vesti gati o n will 
be m o nit ore d t o e ns ure t hat t he ri g hts a n d well -bei n g of t he s u bjects are pr otecte d, t he 
Page 49of 52
reported data are accurate, complete, and verifiable from the source documents, and the study 
is conducted in compliance w ith the current approved protocol (and amendments[s], if 
applicable), with current GCP , and with applicable regulatory  requirements.
The site may  not screen subjects or perform the informed consent process on any  subject until 
it receive sa notification from an appropriate Study Sponsor representative that the site may  
commence conducting study  activities. Monitoring will be conducted periodically  while the 
clinical study  is ongoing. Monitoring methods may  include site visits, telephone, written ,and 
fax co rrespondence. Close -out visits will take place after the last visit of the last subject at the 
site.
A Coordinating Investigator may  be identified by  the Study  Sponsor to review and endorse 
the final study  report. In cases where a Coordinating Investigator is engaged , the Study  
Sponsor will select the Coordinating Investigator based upon their experience, qualifications, 
active study  participation, and their willingness and ava ilability  to take on this role.
13.5 Regulatory Documentation and Records Retention
The Investigator is required to maintain up -to-date, complete regulatory  documentation as 
indicated b y the Study Sponsor and the Investigator ’s files will be reviewed as part of the 
ongoing stud y monitoring. Financial information is to be kept separately . 
Additionally , the Investigator must keep study records and source documents consistent with 
the terms of the clinical study  agreement with the Study  Sponsor . If the Investigator retires, 
relocates, or for an y other reason withdraws from responsibility  of ke eping the study  records, 
then the Study  Sponsor must be notified and suitable arrangements made for retention of 
study  records and source documents needed to comply  with national and international 
regulations.
13.6 Quality Assurance and Quality Contr ol
The Stud y Sponsor will secure agreement from all involved parties to ensure direct access to 
all study  related sites, source data and documents, and reports for the purpose of monitoring 
and auditing b y the Study Sponsor , and inspection by  domestic and foreign reg ulatory  
authorities. Quality  control will be applied to each stage of data handling to ensure that all 
data are reliable and have been processed correctly . Agreements made b y the Study  Sponsor 
with the I nvestigator/Institution and any other parties involve d in the clinical study  will be 
provided in writing as part of the protocol or as a separate agreement.
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
Pa ge 5 0 of 5 2 
1 4 E T HI C S 
T his cli nical st u d y  m ust be c o n d ucte d i n acc or da nce wit h t he et hical pri nci ples c o ntai ne d 
wit hi n: 
T he D eclarati o n of Helsi n ki , a n d i n c o m plia nce wit h t he I C H E 6 G C P  C o ns oli date d 
G ui deli ne, I S O 1 4 1 5 5: 2 0 1 1, a n d t he a p plica ble U S F D A 2 1 C o de of Fe deral Re g ulati o ns. 
S O Ps of t he St u d y  S p o ns or a n d c o ntract researc h or ga nizati o ns partici pati n g i n t he 
c o n d uct of t he cli nical st u d y  a n d all ot her a p plica bl e re g ulati o ns. 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
N otificati o ns a n d ti meli nes f or re p orti n g pr ot oc ol de viati o ns s h o ul d be base d u p o n 
a p plica ble Et hics C o m mittee re q uire me nts 
T he I n vesti gat or m ust e ns ure t hat all pers o n nel i n v ol ve d i n t he c o n d uct of t he st u d y  are 
q ualifie d t o perf or m t heir assi g ne d res p o nsi bilities t hr o u g h rele va nt e d ucati o n, trai ni n g, a n d 
e x perie nce. T he I n vesti gat or a n d all cli nical st u d y staf f m ust c o n d uct t he cli nical st u d y  i n 
c o m plia nce wit h t he pr ot oc ol. De viati o ns fr o m t his pr ot oc ol, re g ulat or y  re q uire me nts ,a n d/ or 
G C P m ust be rec or de d a n d re p orte d t o t he S p o ns or pri or t o data base l oc k. If nee de d, 
c orrecti ve a n d pre ve nti ve acti o n s h o ul d be i de ntifie d, i m ple me nte d, a n d d oc u me nte d wit hi n 
t he st u d y  rec or ds. Use of wai vers t o de viate fr o m t he c li nical pr ot oc ol is pr o hi bite d. 
Bef ore cli nical st u d y  i nitiati o n, t his pr ot oc ol, t he i nf or me d c o nse nt f or m, a n y  ot her writte n 
i nf or mati o n gi ve n t o s u bjects, a n d a n y a d vertise me nts pla n ne d f or s u bject recr uit me nt m ust 
be a p pr o ve d b y a n I R B/I E C. T he I n vesti gat or m ust pr o vi de d oc u me ntati o n of t he I R B/I E C 
a p pr o val t o t he St u d y  S p o ns or . T he a p pr o val m ust be date d a n d m ust i de ntif y t he a p plica ble 
pr ot oc ol, a me n d me nts (if a n y ), i nf or me d c o nse nt f or m, asse nt f or m (if a n y ), all a p plica ble 
recr uiti n g materials, writte n i nf or mati o n f or s u bject, a n d s u bject c o m pe nsati o n pr o gra ms. T he 
I R B/I E C m ust be pr o vi de d wit h a c o p y of t he I B , a n y  peri o dic safet y u p dates, a n d all ot her 
i nf or mati o n as re q uire d b y  l ocal re g ulati o n a n d/ or t he I R B/I E C. At t he e n d of t he st u d y , t he 
I n vesti gat or m ust n otif y  t he I R B/I E C a b o ut t he st u d y ’s  c o m pleti o n. T he I R B/I E C als o m ust 
be n otifie d if t he st u d y  is ter mi nate d pre mat urel y . Fi nall y , t he I n vesti gat or m ust re p ort t o t he 
I R B/I E C o n t he pr o gress of t he st u d y  at i nter vals sti p ulate d b y t he I R B/I E C. 
Vo l u ntar y  i nf or me d c o nse nt m ust be o btai ne d i n writi n g fr o m e ver y s u bject a n d t he pr ocess 
s hall be d oc u me nte d bef ore a n y pr oce d ure s pecific t o t he cli nical i n vesti gati o n is a p plie d t o 
t he s u bject. T he I n vesti gat or m ust ha ve a defi ne d pr ocess f or o btai ni n g c o nse nt. S pecificall y , 
t he I n vesti gat or , or t heir dele gate, m ust e x plai n t he cli nical st u d y  t o eac h p ote ntial s u bject a n d 
t he s u bject m ust i n dicate v ol u ntar y  c o nse nt b y  si g ni n g a n d dati n g t he a p pr o ve d i nf or me d 
c o nse nt f or m. T he s u bject m ust be pr o vi de d a n o p p ort u nit y t o as k q uesti o n s of t he 
I n vesti gat or , a n d if re q uire d b y  l ocal re g ulati o n, ot her q ualifie d pers o n nel. T he I n vesti gat or 
Pa ge 5 1 of 5 2 
m ust pr o vi de t he s u bject wit h a c o p y of t he c o nse nt f or m writte n i n a la n g ua ge t he s u bject 
u n dersta n ds. T he c o nse nt d oc u me nt m ust meet all a p plica ble l o cal la ws a n d pr o vi de s u bjects 
wit h i nf or mati o n re gar di n g t he p ur p ose, pr oce d ures, re q uire me nts, a n d restricti o ns of t he 
st u d y , al o n g wit h a n y  k n o w n ris ks a n d p ote ntial be nefits ass ociate d wit h t he I P  a n d t he st u d y , 
t he a vaila ble c o m pe nsati o n, a n d t he esta b lis he d pr o visi o ns f or mai ntai ni n g c o nfi de ntialit y  of 
pers o nal, pr otecte d healt h i nf or mati o n. S u bjects will be t ol d a b o ut t he v ol u ntar y  nat ure of 
partici pati o n i n t he st u d y  a n d m ust be pr o vi de d wit h c o ntact i nf or mati o n f or t he a p pr o priate 
i n di vi d uals s h o ul d q uesti o ns or c o ncer ns arise d uri n g t he st u d y . T he s u bject als o m ust be t ol d 
t hat t heir rec or ds ma y  be accesse d b y a p pr o priate a ut h orities a n d S p o ns or -desi g nate d 
pers o n nel. T he I n vesti gat or m ust kee p t he ori gi nal, si g ne d c o p y of t he c o nse nt (file i n 
s u bjec t’ s me dical rec or ds ) a n d m ust pr o vi de a d u plicate c o p y t o eac h s u bject acc or di n g t o 
l ocal re g ulati o ns. 
T he St u d y  S p o ns or ass ures t hat t he ke y  desi g n ele me nts of t his pr ot oc ol will be re gistere d o n 
w w w .cli nicaltrials. g o v as re q uire d b y c urre nt re g ulati o ns a n d, if a p plica ble, ot her p u blic 
data bases as re q uire d b y l ocal c o u ntr y  re g ulati o ns. I n a d diti o n, res ults of t his st u d y  will be 
ma de p u blicl y  a vaila ble o n w w w .cli nicaltrials. g o v re gar dless of o utc o me as re q uire d b y 
c urre nt re g ulati o ns a n d, if a p plica ble, i n ot her p u blic data bases as re q uire d b y  l ocal c o u ntr y  
re g ulati o ns. 
1 5 R E F E R E N C E S 
1 5. 1 Refere nces a p plic a ble f or all cli nic al st u dies 
I S O 1 1 9 8 0: 2 0 1 2 O p ht hal mic o ptics -C o ntact le nses a n d c o ntact le ns care pr o d ucts -
G ui da nce f or cli nical i n vesti gati o ns 
I S O 1 4 1 5 5: 2 0 1 1 Cli nical i n vesti gati o n of me dical de vices f or h u ma n s u bjects -G o o d 
cli nical practice 
1 5. 1. 1 U S refere nces a p plic a ble f or cli nic al st u dies 
2 1 C F R Part 1 1 - Electr o nic Rec or ds; Electr o nic Si g nat ures 
2 1 C F R Part 5 0 -Pr otecti o n of H u ma n S u bjects 
2 1 C F R Part 5 6 - I nstit uti o nal Re vie w B oar ds 
2 1 C F R Part 8 1 2 - I n vesti gati o nal De vice E xe m pti o ns 
2 1 C F R Part 5 4 - Fi na ncial Discl os ure b y Cli nical I n vesti gat ors 
Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
T he Calif or nia Bill of Ri g hts 
Pa ge 5 2 of 5 2 
1 5. 2 Refere nces f or t his cli nic al st u d y 
Pre mar ket N otificati o n ( 5 1 0( k)) G ui da nce D oc u me nt f or Dail y W ear C o ntact Le nses 
I S O 1 1 9 8 0: 2 0 1 2 O p ht hal mic o ptics -C o ntact le nses a n d c o ntact le ns care pr o d ucts -
G ui da nce f or cli nical i n vesti gati o ns 
I S O 1 4 1 5 5: 2 0 1 1 Cli nical i n vesti gati o n of me dical de vices f or h u ma n s u bjects -G o o d 
cli nical practice 
D u m blet o n K, W o o ds C, J o nes L , F o n n D, Sar wer D. Patie nt a n d Practiti o ner C o m plia nce 
wit h Silic o ne H y dr o gel a n d Dail y  Dis p osa ble Le ns Re place me nt i n t he U nite d States. Eye 
C o nt act Le ns Alc o n  - B usi ness Use O nl y   Effecti ve D ate:  
D oc u me nt:  Versi o n:  
St at us:  E f f e c t i v e 
Pri nte d B y:  Pri nt Date:  1 . 0 ;  C U R R E N T ;  M o s t - R e c e n t ;  E f f e c t i v e T D O C - 0 0 5 4 0 2 7 P r o t o c o l  -  C l i n i c a l 2 4- A u g- 2 0 1 7 
. 2 0 0 9: 3 5( 4): 1 6 4 -1 7 1. 
                                                                                                                
                                                                                     
Date/Time 
(mm/dd/yyyy GMT): Signed by: Justification :
08/24/2017 13:43:11
08/23/2017 17:49:11
08/23/2017 17:36:08
08/23/2017 17:36:08
Alcon - Business Use Only   Effective Date:  
Document:  Version:  
Status:  
Printed By: Print Date:  
Effective
1.0; CURRENT; Most-Recent; Effective
TDOC-0054027
Protocol - Clinical
24-Aug-2017
